Sugi Predict

Sugi Predict / Compounds / SCHEMBL2596044

SCHEMBL2596044

SCHEMBL2596044

CC1(C)OB(c2ccc(S(C)(=O)=O)nc2)OC1(C)C

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.45
▸ CA2 P00918 5/20 0.45
▸ CA9 Q16790 5/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA3 P07451 1/20 0.45
▸ CA4 P22748 1/20 0.45
▸ CA6 P23280 1/20 0.45
▸ CA5A P35218 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CA14 Q9ULX7 1/20 0.45
▸ CA5B Q9Y2D0 1/20 0.45
▸ DGAT1 O75907 2/20 0.43
▸ LPL P06858 9/20 0.41
▸ LIPG Q9Y5X9 9/20 0.41
▸ PDGFRB P09619 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ ALPL P05186 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29789624 1.00 CA1 (0.45) CA1CA2CA9CA12CA3
SCHEMBL16014422 0.86 DGAT1 (0.45) CA1CA2CA9CA12CA3
SCHEMBL16014673 0.83 CA1 (0.42) CA1CA2CA9CA12CA3
SCHEMBL16014675 0.81 LPL (0.44) CA1CA2CA9CA12CA3
SCHEMBL16015016 0.80 DGAT1 (0.46) CA1CA2CA9CA12CA3
SCHEMBL20578022 0.79 PIK3CD (0.33) CA1CA2CA9CA12CA4
SCHEMBL18426166 0.79 DGAT1 (0.46) CA1CA2CA9CA12CA3
SCHEMBL16023158 0.79 DGAT1 (0.43) CA1CA2CA9CA12CA3
SCHEMBL13362060 0.78 CA1 (0.54) CA1CA2CA9CA12CA3
SCHEMBL18128145 0.77 CA1 (0.42) CA1CA2CA9CA12CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665733-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 Bristol-Myers Squibb Company (US) 2025-12-24 — — EP disclosed
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2025-04-01 — — US disclosed
US-20240327390-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2024-10-03 — — US disclosed
EP-3617195-B1 NOVEL TETRAHYDRONAPHTHYL UREA DERIVATIVES AS INHIBITORS OF TROPOMYOSIN RECEPTOR KINASE A FOR THE TREATMENT OF PAIN MOCHIDA PHARM CO LTD (JP) 2024-08-28 — — EP disclosed
WO-2024173323-A1 AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 BRISTOL-MYERS SQUIBB COMPANY (US) 2024-08-22 — — WO disclosed
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-07-18 — — US disclosed
EP-3929194-B1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2024-04-17 — — EP disclosed
US-20240116946-A1 SARS-COV2 MAIN PROTEASE INHIBITORS GILEAD SCIENCES, INC. 2024-04-11 — — US disclosed
CN-110831926-B Tetrahydronaphtyl urea derivatives 持田制药株式会社 2023-11-21 — — CN disclosed
US-RE49700-E1 Substituted nitrogen containing compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2023-10-17 — — US disclosed
US-20150210624-A1 DEUTERATED 4-HYDROXYBUTYRIC ACID ANALOGS CONCERT PHARMACEUTICALS, INC. 2015-07-30 — — US disclosed
WO-2015086506-A1 FUSED IMIDAZOLE AND PYRAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 — — WO disclosed
EP-2751109-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS Incyte Corporation (US) 2014-07-09 — — EP disclosed
EP-2719697-A1 PYRIDONAPHTHYRIDINE PI3K/MTOR DUAL INHIBITORS AND PREPARATION AND USE THEREOF Xuanzhu Pharma Co., Ltd. (CN) 2014-04-16 — — EP disclosed
EP-2566328-A1 INDAZOLES GlaxoSmithKline LLC (US) 2013-03-13 — — EP disclosed
WO-2013033569-A1 HETEROCYCLYLAMINES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2013-03-07 — — WO disclosed
WO-2012174312-A2 BENZIMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2012-12-20 — — WO disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 — — WO disclosed
WO-2008106204-A1 MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X-PHARMACEUTICALS, INC. (US) 2008-09-04 — — WO disclosed
WO-2008106204-A1 MACROLIDE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X-PHARMACEUTICALS, INC. (US) 2008-09-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327390-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS NR0B1, GRK1, GRIN1 CA1 2587/4885CA2 2643/4885CA9 4255/4885
US-20240116946-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE CA1 2925/4885CA2 426/4885CA9 1242/4885
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 CA1 4187/4885CA2 3299/4885CA9 4611/4885
US-20240239807-A1 SARS-COV2 MAIN PROTEASE INHIBITORS ACE2, TMPRSS2, ACE CA1 2925/4885CA2 426/4885CA9 1242/4885
US-20150210624-A1 DEUTERATED 4-HYDROXYBUTYRIC ACID ANALOGS HCRTR2, HCRTR1, HSD3B1 CA1 947/4885CA2 454/4885CA9 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.